Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Sham-Controlled Study to Evaluate AXO-Lenti-PD in Parkinson's Disease

Next Previous
Trial Profile

A Phase III, Randomized, Sham-Controlled Study to Evaluate AXO-Lenti-PD in Parkinson's Disease

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AXO Lenti PD (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Oxford BioMedica; Sio Gene Therapies [CEASED]

    • Most Recent Events

    • 29 Oct 2020 According to an Axovant Gene Therapies media release, manufacturing of several GMP batches is now underway and planned at Oxford Biomedica with a goal of generating material for use in future clinical trials as soon as possible and the company expects to provide an update on program timelines in the first quarter of 2021 or as program timelines are clarified.
    • 29 Oct 2020 According to an Axovant Gene Therapies media release, based on new information received from manufacturing partner Oxford Biomedica in mid-October regarding delays in CMC data and third-party fill/finish issues, the development of a suspension-based manufacturing process for AXO-Lenti-PD will take longer than expected. The company believes that it is unlikely hat the trial will enroll patients by the end of calendar year 2021.
    • 08 Apr 2020 According to an Axovant Gene Therapies media release, enrollment of the first randomized subject is expected in 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top